Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Men and women, 18 years of age or greater~Confirmed HIV infection by ELISA and Western blot~No changes in antiretroviral regimen within the prior 3 months--Individuals not currently taking antiretroviral therapy will be eligible. Individuals requiring medically indicated adjustments of antiretroviral therapy during the course of the study will be eligible.~Confirmed HCV infection, and no current or recent (within the past 3 months) HCV treatment and no plans to start HCV antiviral therapy in the foreseeable future.~H-MRS liver fat content greater than 5 percent and confirmed steatosis on liver biopsy within 1 year~Fasting glucose less than 126 mg/dL~Platelets greater than or equal to 75,000/uL; INR less than 1.6~Willingness to avoid medications and herbal supplements which may increase the risk of bleeding for one week prior to and one week following liver biopsy (e.g. aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), Vitamin E, fish oil and gingko biloba).~Willingness to restrict physical activity 72 hours after liver biopsy~If premenopausal female, willingness to use 2 forms of effective birth control on this study to avoid pregnancy.~Have a primary care physician~Willingness to have specimens stored.~EXCLUSION CRITERIA:~Current thiazolidinedione use or use in the last 6 months, known allergy or sensitivity to a thiazolidinedione~Use of insulin or other oral hypoglycemics, or known diabetes~Current pregnancy, breast feeding, or pregnancy within the past 6 months or desire to become pregnant within the next 2 years.~Child-Pugh-Turcotte (CPT) score greater than class A~ALT greater than 4 times the upper limit of normal~Current or history of heart failure (New York Heart Association \[NYHA\] Class III or IV cardiac status)~Hemoglobin level less than 9g/dL~Active or ongoing infection with Hepatitis A or B~Known or suspected liver disease such as autoimmune hepatitis, Wilson's disease, alpha-1-antitrypsin deficiency, cystic fibrosis, hemochromatosis, glycogen storage disease, amyloidosis, primary biliary cirrhosis, sclerosing cholangitis, or any primary or secondary hepatic tumor~Current alcohol/substance abuse~Use of growth hormone, prednisone or other anabolic agents (except for physiologic testosterone replacement) currently or within the past 3 months. One day or less of corticosteroid within the prior 90 days of screening is allowed as is stable dose inhalation corticosteroids~Concurrent use of ketoconazole~Active opportunistic infection (except thrush) or neoplasm (except Kaposi's sarcoma, skin cancer, cancer of the cervix or anus)~Any known contraindications to percutaneous liver biopsy including elevated PT/PTT~Severe psychiatric illness that would interfere with adherence to protocol requirements~Current treatment with interleukin-2, interferon-alpha, or other investigational agent(s) within the past 6 months (This does not pertain to ARVs obtained through expanded access)~Any significant medical condition for which the investigator believes a liver biopsy or participation in the research protocol may be contraindicated~Any contraindication to MRI scan, including excess body size

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: EXPERIMENTAL): pioglitazone 45 mg daily for 48 weeks
- Placebo (Type: PLACEBO_COMPARATOR): one capsule daily for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).